India · Delayed Price · Currency is INR Gland Pharma Statistics
Total Valuation
Gland Pharma has a market cap or net worth of INR 293.40 billion. The enterprise value is 264.40 billion.
| Market Cap | 293.40B |
| Enterprise Value | 264.40B |
Important Dates
The last earnings date was Wednesday, January 28, 2026.
| Earnings Date | Jan 28, 2026 |
| Ex-Dividend Date | Aug 14, 2025 |
Share Statistics
| Current Share Class | 164.76M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.02% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 38.28% |
| Float | 79.35M |
Valuation Ratios
The trailing PE ratio is 34.63 and the forward PE ratio is 26.00.
| PE Ratio | 34.63 |
| Forward PE | 26.00 |
| PS Ratio | 4.80 |
| PB Ratio | 3.07 |
| P/TBV Ratio | 3.20 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 31.21 |
| EV / Sales | 4.33 |
| EV / EBITDA | 18.39 |
| EV / EBIT | 25.56 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.21 |
| Debt / FCF | n/a |
| Interest Coverage | 39.63 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 10.55% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 14.05M |
| Profits Per Employee | 1.95M |
| Employee Count | 4,351 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Gland Pharma has paid 4.00 billion in taxes.
| Income Tax | 4.00B |
| Effective Tax Rate | 32.07% |
Stock Price Statistics
The stock price has increased by +22.56% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +22.56% |
| 50-Day Moving Average | 1,734.28 |
| 200-Day Moving Average | 1,803.00 |
| Relative Strength Index (RSI) | 47.85 |
| Average Volume (20 Days) | 13,945 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Gland Pharma had revenue of INR 61.13 billion and earned 8.47 billion in profits. Earnings per share was 51.42.
| Revenue | 61.13B |
| Gross Profit | 35.98B |
| Operating Income | 10.34B |
| Pretax Income | 12.47B |
| Net Income | 8.47B |
| EBITDA | 14.19B |
| EBIT | 10.34B |
| Earnings Per Share (EPS) | 51.42 |
Balance Sheet
The company has 32.02 billion in cash and 3.02 billion in debt, with a net cash position of 29.00 billion.
| Cash & Cash Equivalents | 32.02B |
| Total Debt | 3.02B |
| Net Cash | 29.00B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 95.63B |
| Book Value Per Share | 580.47 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 58.86%, with operating and profit margins of 16.92% and 13.86%.
| Gross Margin | 58.86% |
| Operating Margin | 16.92% |
| Pretax Margin | 20.40% |
| Profit Margin | 13.86% |
| EBITDA Margin | 23.21% |
| EBIT Margin | 16.92% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 18.00, which amounts to a dividend yield of 0.97%.
| Dividend Per Share | 18.00 |
| Dividend Yield | 0.97% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.02% |
| Shareholder Yield | 0.96% |
| Earnings Yield | 2.89% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |